AR025969A1 - Homologos de ifn-alfa - Google Patents
Homologos de ifn-alfaInfo
- Publication number
- AR025969A1 AR025969A1 ARP000105267A ARP000105267A AR025969A1 AR 025969 A1 AR025969 A1 AR 025969A1 AR P000105267 A ARP000105267 A AR P000105267A AR P000105267 A ARP000105267 A AR P000105267A AR 025969 A1 AR025969 A1 AR 025969A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptides
- homologs
- homologies
- alfa
- ifn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
Abstract
Se proveen homologos de alfa interferon (tanto ácidos nucleicos como polipéptidos). Se proveen composiciones que incluyen estos polipéptidos y ácidosnucleicos, células recombinantes que comprenden dichos polipéptidos de ácido nucleico homologos dein terferon, métodos para la elaboracion de nuevos homologos,antecuerpos para los nuevos homologos, y métodos de uso de los nuevos homologos. También se proveen sistemas integrados que comprenden las secuencias de losácidos nucleicos o polipéptidos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41518399A | 1999-10-07 | 1999-10-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR025969A1 true AR025969A1 (es) | 2002-12-26 |
Family
ID=23644696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000105267A AR025969A1 (es) | 1999-10-07 | 2000-10-08 | Homologos de ifn-alfa |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1238082A2 (es) |
JP (1) | JP2003511031A (es) |
CN (1) | CN1451045A (es) |
AR (1) | AR025969A1 (es) |
AU (1) | AU8001300A (es) |
CA (1) | CA2385045A1 (es) |
MX (1) | MXPA02003492A (es) |
WO (1) | WO2001025438A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7300775B2 (en) | 1999-12-29 | 2007-11-27 | Verenium Corporation | Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents |
US7521216B2 (en) | 1999-12-29 | 2009-04-21 | Verenium Corporation | Nitrilases and methods for making and using them |
US7608445B1 (en) | 1999-12-29 | 2009-10-27 | Verenium Corporation | Nitrilases, nucleic acids encoding them and methods for making and using them |
FR2822845B1 (fr) * | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
FR2823763A1 (fr) * | 2001-04-18 | 2002-10-25 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'interferon alpha 6 |
FR2823764B1 (fr) | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
FR2824333B1 (fr) * | 2001-05-03 | 2003-08-08 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 5 |
FR2825716B1 (fr) * | 2001-06-11 | 2004-09-24 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 7 |
US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
WO2003106415A2 (en) | 2002-06-13 | 2003-12-24 | Diversa Corporation | Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid |
DE60332358D1 (de) | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
KR20050086498A (ko) * | 2002-11-18 | 2005-08-30 | 맥시겐, 인크. | 인터페론-알파 폴리펩티드 및 접합체 |
US7314613B2 (en) * | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
AU2005245918A1 (en) * | 2004-05-19 | 2005-12-01 | F. Hoffmann-La Roche Ag | Interferon-alpha polypeptides and conjugates |
BRPI0609809A2 (pt) * | 2005-05-18 | 2011-10-11 | Maxygen Inc | polipeptìdeo isolado ou recombinante, conjugado, composição, polinucleotìdeo isolado ou recombinante, célula hospedeira, vetor, métodos para preparar o polipeptìdeo, para preparar um conjugado, para inibir replicação de um vìrus em células infectadas com o vìrus para reduzir o numero de cópias de um vìrus em células infectadas com o vìrus, para reduzir o nìvel de rna de hcv no soro de um paciente infectado com hcv, para reduzir o nìvel de dna de hbv em soro de um paciente infectado com hbv e para reduzir o nìvel de rna de hiv em soro de um paciente infectado com hiv, e, uso do polipeptìdeo ou do conjugado |
EP2115153B1 (en) | 2007-03-01 | 2013-06-05 | BP Corporation North America Inc. | Nitrilases, nucleic acids encoding them and methods for making and using them |
US7625555B2 (en) * | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801685A (en) * | 1981-08-14 | 1989-01-31 | Hoffmann-La Roche Inc. | Microbial production of mature human leukocyte interferon K and L |
US5098703A (en) * | 1982-01-15 | 1992-03-24 | Cetus Corporation | Interferon-alpha 76 |
WO2000052153A2 (en) * | 1999-03-02 | 2000-09-08 | Maxygen, Inc. | Method to identify ligands for orphan receptors |
-
2000
- 2000-10-06 MX MXPA02003492A patent/MXPA02003492A/es not_active Application Discontinuation
- 2000-10-06 CN CN00816713A patent/CN1451045A/zh active Pending
- 2000-10-06 CA CA002385045A patent/CA2385045A1/en not_active Abandoned
- 2000-10-06 AU AU80013/00A patent/AU8001300A/en not_active Abandoned
- 2000-10-06 WO PCT/US2000/027781 patent/WO2001025438A2/en not_active Application Discontinuation
- 2000-10-06 JP JP2001528590A patent/JP2003511031A/ja not_active Withdrawn
- 2000-10-06 EP EP00970665A patent/EP1238082A2/en not_active Withdrawn
- 2000-10-08 AR ARP000105267A patent/AR025969A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2003511031A (ja) | 2003-03-25 |
WO2001025438A2 (en) | 2001-04-12 |
CN1451045A (zh) | 2003-10-22 |
WO2001025438A3 (en) | 2002-07-11 |
CA2385045A1 (en) | 2001-04-12 |
MXPA02003492A (es) | 2002-08-20 |
EP1238082A2 (en) | 2002-09-11 |
AU8001300A (en) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR025969A1 (es) | Homologos de ifn-alfa | |
BR9912448A (pt) | Composto, composição farmacêutica, e, processos de indução de biossìntese de citoquina em um mamìfero, de tratamento de uma doença virótica em um mamìfero, e de tratamento de uma doença neoplásica em um mamìfero | |
PA8426301A1 (es) | Bikunina humana | |
ATE252639T1 (de) | Modifizierter, das dorsalgewebe beeinflussender faktor | |
TR200100056T2 (tr) | Nörotrofik faktörler | |
ES2186015T3 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. | |
NO965627L (no) | Nytt cytokin betegnet lerk-5 | |
BR0013966A (pt) | Compostos espiroeterocìclicos úteis como inibidores reversìveis de proteases de cisteìna | |
SE8501709L (sv) | Forbettringar inom eller som henfor sig till interleukinterapi | |
BR0215405A (pt) | Composições e processos de uso de collajolie | |
DE60144145D1 (de) | Subtilisin-variante | |
BR9916894A (pt) | ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek | |
TR200002218T2 (tr) | 2-(Pürin-9-il)-Tetrahidrofüran -3,4-Diol türevleri | |
BR9807848B1 (pt) | Composto de arilsulfonamidas e análogos, bem como composição farmacêutica e uso dos mesmos. | |
SV1999000016A (es) | Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv | |
AR018023A1 (es) | Procedimiento para la fabricacion de polipeptidos con glicosilacion apropiada | |
ES2192839T3 (es) | Timosina beta 4 oxidada. | |
SE9802729D0 (sv) | Novel Compounds | |
DK1097173T3 (da) | Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler | |
ES2080800T3 (es) | Polipeptidos y analogos de polipeptidos con actividad inhibitoria frente a la elastasa humana. | |
DK424385A (da) | Aminobenzopyranoner, deres fremstilling og anvendelse som antipsychotiske og anxiolytiske midler | |
DK0495918T3 (da) | Aminosyre-beta-lyaseenzyminhibitorer som deodoranter | |
IT8519040A0 (it) | Cloni di cdna di eritropietina umana. | |
DE69426121D1 (de) | Gen grb3-3, variante und ihre verwendungen | |
FI904965A0 (fi) | Nya alfa-glukosidasinhibitorer. |